Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kymera Therapeutics Inc.
Headquarters: Watertown, MA, United States of America
Website: http://www.kymeratx.com/
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Nello Mainolfi, PhD
Number Of Employees: 188
Enterprise Value: $2,618,036,758
PE Ratio: -9.22
Exchange/Ticker 1: NASDAQ:KYMR
Exchange/Ticker 2: N/A
Latest Market Cap: $1,923,644,160
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Aug 24, 2024
Finance
Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing
Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
BioCentury | Jan 5, 2024
Finance
Catalysts drive follow-ons for Dyne, Longboard, Voyager in first week of 2024
Seven NASDAQ-listed biotechs together raise more than $1.6B in year’s first days, with Arrowhead drawing the largest amount
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | Sep 27, 2023
Finance
Sept. 26 Quick Takes: Early IgG readout lifts Immunovant
Plus: Acesion raises $48M for atrial fibrillation treatment and updates from A-Alpha, Amgen, Ionis, Pliant, Qihan, Novo, Evotec, ICER, Caribou and AbbVie
BioCentury | Mar 21, 2023
Product Development
March 20 Quick Takes: Latest data add to Karuna’s case in schizophrenia
Plus: two Sangamo partnerships end, Gilead adds Nurix’s degrader
BioCentury | Feb 2, 2023
Product Development
Competition heats up in hidradenitis suppurativa
Humira has competition coming from IL-17 biologics, oral small
BioCentury | Jan 5, 2023
Management Tracks
Sanofi’s Sarchi heads to Replimune
Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more
Items per page:
1 - 10 of 66